Abstract. The pharmacological mechanisms of a synthetic compound 1-benzyl-3-(5'-hydroxymethyl-2'-furyl) indazole (YC-1) in preventing smooth muscle cell proliferation remains to be elucidated. The present study was aimed to explore the effects of YC-1 on certain molecules responsible for cell proliferation, including transforming growth factor (TGF)-b1, soluble guanylyl cyclase (sGC) and focal adhesion kinase (FAK). The in vivo assay was correlated to the in vitro results of YC-1 on vascular stenosis. YC-1 was applied topically via a pluronic gel onto the balloon-injured rat carotid arteries, which were then harvested two weeks later for histological analysis. Our in vitro results showed that TGF-b1 was suppressed by YC-1 by 50%. The translational level of sGC was threefold activated by YC-1 while the transcription level of sGC was increased up to 24-fold. FAK, the molecule responsible for cell proliferation and migration, was suppressed by YC-1 on the translational levels for 72%. These in vitro results were in consistent with the in vivo observation that the area ratio of neointima to media was reduced by YC-1. This study provides insights into the pharmacological mechanisms of YC-1 in preventing abnormal smooth muscle cell proliferation and thus supports the use of YC-1 as an adjuvant therapy for balloon injury-induced restenosis.
Introduction
Percutaneous transluminal coronary angioplasty (PTCA), a balloon-catheter-based interventional procedure, is a non-surgical modality for treating coronary atherosclerotic stenosis. However, the occurrence of restenosis within 6 months in 30% -50% patients following the angioplasty procedure has been the major drawback of PTCA (1, 2) . Aside from mechanical vessel recoil, abnormal proliferation of vascular smooth muscle cells (VSMCs) in the intimal layer has been referred as the main cause of restenosis. It is generally believed that mechanical denudation of the vascular endothelial cells and traumatization of the media result in the activation of multiple signal transduction pathways that ultimately alter SMC proliferation and migration (3) . An important therapeutic aim to treat neointima formation is to inhibit VSMC proliferation without interfering with endothelial or other cell proliferation.
1-Benzyl-3-(5'-hydroxymethyl-2'-furyl) indazole (YC-1), a benzyl indazole derivative ( Fig. 1 ) (4), exerts vasorelaxing effects in rat aorta (5) as well as inhibitory effects on platelet aggregation (6) and cell proliferation (4) . All these effects have been linked to the activation of soluble guanlylyl cyclase (sGC) by YC-1 (7, 8) . sGC is a heterodimeric enzyme (ab) containing a noncovalently bound prosthetic heme group necessary for NO-induced stimulation. Since NO has been implied to play a major role in preventing the balloon injuryinduced neointima formation (9, 10) and is a potent activator for cGMP production, the inhibitory effect of NO on restenosis may be in common to that of YC-1. To identify if the preventive effects of YC-1 on vascular stenosis were mediated by activation of sGC, a selective inhibitor of nitric oxide-sensitive GC, 1H-[1,2,4]oxadiazolo [4,3-a] quinoxalin-1-one (ODQ), was applied concomitantly with YC-1 on injured vessels.
The enhancement of YC-1 on sGC activation and vasorelaxation was in agreement with a recent report using YC-1 to block angioplasty-induced stenosis in rat carotid arteries (11) . However, the molecular mechanism of YC-1 in preventing balloon injury-induced stenosis remains to be elucidated. Transforming growth factor (TGF)-b1 and focal adhesion kinase (FAK), the two important modulators responsible for SMC proliferation and migration, were evaluated in the present study to explore the molecular mechanisms of YC-1 in preventing neointima formation. It has been shown that SMCs in injured rat carotid arteries secreted significant amount of TGF-b 1 (12) . There was a sustained increases in TGF-b1 mRNA levels over the two weeks of injured time with a substantial neointima thickening (13) . It would be of great interest to study if YC-1 can inhibit the extracellular secretion of TGF-b1 from SMCs. FAK was another molecule attracting a significant amount of attention in the studies regarding the balloon injury-induced intimal hyperplasia. The FAK gene encodes a novel nonreceptor tyrosine kinase (p125 FAK ) involved in signal transduction pathways responsible for cell adhesion, motility, and proliferation (14 -16) . Over-expression of the FAK gene has been found in balloon injury-induced intimal hyperplasia but relative lack of expression in healthy vessels, suggesting FAK up-regulation may be part of a mechanism for migration and proliferation during this process (17) . To sum up, the present study was aimed to elucidate whether the involvement of YC-1 in the inhibition of neointima formation was related to TGF-b1, sGC, and FAK expression thus to shed the light into the molecular mechanisms of YC-1 as a potential therapeutic remedy for treating PTCA-induced restenosis.
Materials and Methods

Cell culture
Rat thoracic aorta VSMCs (A10 VSMC) were obtained from the Culture Collection and Research Center (CCRC; Hsinchu, Taiwan). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (vol / vol) fetal bovine serum (FBS), 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units of penicillin, and 100 mg of streptomycin per ml. The cells were kept in a humidified 5% CO 2 -95% air incubator at 37°C. Cells were cultured in DMEM medium containing various concentrations of YC-1 with 0.5% serum (for sGC study) or 15% serum (for TGF-b 1 and FAK study). Cells cultured in medium containing 0.5% serum without YC-1 to maintain the minimal physiologic condition served as a negative control. Cells cultured in medium containing 15% serum without YC-1 served as positive control.
ELISA assay of extracellular level of TGF-b
VSMCs were cultured in the presence of 0.3 -300 m M of YC-1 for 24 h at 37°C. The culture medium was collected and immuno-reacted with anti-TGF-b to determine the extracellular secretion of TGF-b in response to YC-1 treatment by an ELISA reader. ELISA kits for TGF-b1 were purchased from Amersham Pharmacia Biotech (Buckinghamshire, UK). The assay procedure was based on the protocols provided by the manufacturer. Briefly, samples extracted from VSMCs were aliquoted into ELISA plates. Following 1-h incubation at 37°C, the conjugated complexes were washed 4 times with wash buffer containing 0.01 M phosphate buffer saline, pH 7.4 and 0.2% Tween 20. Antibodies were then added to the sample complexes for 1-h incubation at 37°C followed by reaction with biotinylated second antibodies for an additional hour. Conjugation with streptavdin-HRP was thereafter carried out for 30 min at 37°C. After washing 4 times with wash buffer, 3,3',5,5'-tetramethylbenzidine / hydrogen peroxide solution in 20% (v / v) dimethylformamide as substrates was added to plates for 30 min of incubation at room temperature. The O.D. reading for each sample was then performed at 450 nm by a spectrophotometer (Beckman, Fullerton, CA, USA). The actual concentrations were then converted from the corresponding standards.
RT-PCR analysis of sGC b1 subunit in SMC
Approximately 1´10 7 SMCs cultured in 3 -300 mM of YC-1 were re-suspended in 1 ml of lysis buffer containing 4 M guanidine thiocyanate, 0.5% sarcosyl, 25 mM sodium citrate, and 0.1 M b -mercaptoethanol at pH 7.0, followed by phenol extraction, isopropanol precipitation, and ethanol precipitation. Quality of RNA was examined by agarose gel electrophoresis. Two micrograms of total RNA was annealed with 6 mM random hexamer in a total volume of 50 ml. The cDNA synthesis was performed in a 100-m l mixture containing 0.5 mM each dATP, dCTP, dGTP; 40 m M dTTP, 40 mM biotin-16-dUTP (Boehringer Mannheim, Mannheim, Germany), 10 mM DTT, 0.5 units / m l Human Placental Ribonuclease Inhibitor (HT Biotechnology Ltd., Cambridge, UK), and 200 units of Superscript RT II (Gibco-BRL, Gaithersburg, MD, USA). The following primers were used to determine the sGC b1 subunit mRNA by PCR: 591 bp, sense primer, 5'-ATG TAY GGI TTY GTI AAY CAY GC-3' and antisense primer, 5'-TCY TCR TAR AAR TCY TCY TCY TT-3'. Among the above sequences, "Y" stands for the mixture deoxynucleotides of C / T, "I" stands for the inosine, and "R" stands for the mixture deoxynucleotides of A / G. The PCR condition was 35 cycles with 94°C for 1 min, 50°C for 1 min and 72°C for 1 min. The RT-PCR products were then resolved in 1.5% agarose gel and subjected to quantitative analysis by means of digital computing system (Sakoi NTSC Inc., Tokyo).
Western blot analysis of sGC and FAK by YC-1 treatment in VSMC
Approximatly 1´10 7 SMCs cultured in 0.03 -300 m M of YC-1 were resuspended in protein lysis buffer containing 75 mM NaCl, 2 mM D,L-dithiothreitol (DTT), 2 mM EDTA, 0.2 m M benzamidine, 0.5 mM PMSF, 1 m M pepstatin A, and 50 mM triethanolamine (TEA) / HCl, pH 7.4. Equal loading of protein lysate (20 m g) measured by Bradford assay was then subjected to 7.5% (w / v) SDS / PAGE gel for protein separation followed by immunoblotting using an antibody against 70-kd sGC b1-subunit (Cayman Chemical, Ann Arbor, MI, USA) or 125-kd FAK (Transduction Laboratories, Lexington KY, USA) with 1:2000 or 1:1000 dilution, respectively. After conjugation with a biotinylated antirabbit IgG at a 1:5000 dilution, the protein levels were then detected using an ECL kit (Amersham Pharmacia Biotech) according to the protocols provided by the manufacturer.
Preventive effects of YC-1 on neointima formation
Twenty-four Sprague Dawley rats divided into four groups were studied in this project. The first group of rats subjected to surgical isolation of carotid arteries without balloon injury served as a normal control. The second group of rats receiving balloon injury without drug treatment served as a sham control. Rats receiving both balloon injury and 300 m M YC-1 with or without 300 m M ODQ treatment served as the study groups. For the fifth group, the balloon-injured rats received ODQ alone to confirm the inhibitory effects of YC-1 on neointima formation. All experimental procedures were executed following the Guidelines for the Chinese Society for the Laboratory Animal Science, Taiwan. For balloon injury, rats were anesthetized using 10:1 ketamine and xylozine and the left site of the common artery was exposed for balloon catheter insertion. After locating the bifurcation of external and internal carotid arteries, the internal carotid arteries were temporarily ligated. The cranial side of the external artery was permanently ligated and the region close to bifurcation was nicked through which a balloon catheter was introduced into the common carotid artery. Until the tip of a balloon catheter reached the common carotid artery about 3 cm over the bifurcation, a 1.5-atm pressure was applied to inflate the balloon. The inflated balloon was then pulled back and forth 3 times to injure the vessel wall. Ten percent of pluronic gel containing 300 mM of YC-1 was then applied surrounding the rat common carotid arteries right after balloon injury. Two weeks after balloon injury, rats were sacrificed with overdose of pentobarbital injection. Tissue sectioning was performed at the desktop microtome with 10-m m thickness. Ten sections from each group were averaged to evaluate the area ratio of neointima to media layers. The tissue sections were stained by Weigert's method using Weigert's Iron Hematoxylin solution, Resorcin-Fuchsin solution, and Van Gieson's solution to delineate the elastic fibers over which are the neointima layers. After staining, the pictures of the sections were captured for image analysis via the digital program Matrox Inspector (Matrox Electronic Systems Ltd., Quebec, Canada).
Data analyses
Quantitative histologic measurement of intimal thickening was performed by an observer blinded to treatment regimen using computerized digital microscopic planimetry. Neointima formation was estimated 14 days after balloon injury. Measurements of the following parameters were made and used for further calculations: lumen area, neointima area delineated by the internal elastic lamina, and total artery wall area as delineated by the external lamina. The ratio of neoimtimal to media area for both controls and balloon-injured coronary arteries was recorded and subjected to statistical analysis.
Statistics
Data are expressed as the mean ± S.D. Two-way ANOVA was applied to analyze the continuous variables followed by Newman-Keuls test. A P value <0.05 is considered statistically significant.
Results
Inhibition of YC-1 of TGF-b1 secretion by A10 cells
Secretion of TGF-b 1 from A10 VSMCs was evaluated by ELISA assay under the effects of YC-1 treatment. The positive control with 15% serum stimulation results in TGF-b1 secretion for about 3300 arbitrary units. With 0.5% serum starvation as a basal level control, TGF-b 1 content dropped down to 950 arbitrary units. A10 SMCs cultured in 15% serum medium were subjected to 0.3 to 300 m M YC-1 treatment to determine if YC-1 treatment suppressed TGF-b1 secretion. Our results demonstrated a significant inhibition of 300 m M YC-1 on TGF-b1 secretion for about 50% when compared to the serum control (Fig. 2) . However, the concentration of YC-1 lower than 30 m M showed no significant effects on TGF-b1 secretion.
The stimulatory effects of YC-1 on GC mRNA
It has been shown that cGMP was increased by YC-1 and GC is the key enzyme responsible for cGMP production (4, 6). It was then rational to predict the gene expression of GC to be regulated by YC-1 at the transcriptional level. The mRNA level of GC b1 subunit was increased significantly by YC-1 in a concentrationdependent manner ranging from 3 mM to 300 m M as compared to the serum-stimulated control (Fig. 3A) . The increase of sGC mRNA levels by 30 m M and 300 m M of YC-1 were about 10-and 24-fold as compared to the 0.5% serum control with GAPDH normalization, respectively (Fig. 3B) . These results demonstrated a stimulatory effect of YC-1 on GC b 1 subunit at the transcription level.
Effects of YC-1 on the protein levels of GC and FAK
In addition to the effects on gene expression level, activation of YC-1 on GC at the translational level in VSMC was also determined. Figure 4 shows a slightly concentration-dependent effect of YC-1 on protein expression level of GC b 1 subunit with 300 m M of YC-1 demonstrating the strongest stimulation. Under a similar condition, FAK protein expression level was on the other hand significantly suppressed by YC-1 in a dose-dependent manner (Fig. 5) . While 0.03 mM of YC-1 showed very minute effects on the protein expression level of FAK, this 125-kd protein was significantly reduced by 3 mM and 300 m M of YC-1 for 40% and 72%, respectively, as compared to the 15% serum control.
The preventive effects of YC-1 on in vivo neointima formation
Our in vitro results were implicated for the preventive effects of YC-1 on balloon injury-induced neointima formation in rat carotid arteries. Two weeks after the balloon injury, arteries were then harvested for histological analysis. Tissue sections were stained by Weigert's method to visualize the elastic fibers and the neointima layer. The balloon injury-induced vascular stenosis was evident in Fig. 6B as compared to normal artery (Fig. 6A) . With application of YC-1 (300 m M) via pluronic gel onto injured artery (Fig. 6C) , the neointima formation was significantly suppressed as compared to the sham control (Fig. 6B) . With concomitant application of YC-1 and ODQ (300 mM), the inhibition of YC-1 on neointima formation was reduced (Fig. 6D) , whereas ODQ alone did not affect the intimal hyperplasia (Fig. 6E) . With computerized image analysis, the areas of neointima and media layers for each section were calculated. The present study demonstrated a 55% reduction on the area ratio of neointima to media by YC-1 as compared to the balloon-injury control, whereas addition of ODQ reduced such inhibition to only 6.9% (Fig. 7) .
Discussion
The primary aim of this study is to explore the molecular mechanism of YC-1 in preventing balloon injury-induced stenosis in rat carotid arteries. VSMC The quantitative analysis demonstrated a 72% reduction of FAK protein level by 300 mM of YC-1 as compared to the 15% serum control. *, ** indicate a P value <0.05 and <0.01, respectively, as compared to the 15% serum control, N = 6.
proliferation is regarded as an essential event leading to the balloon angioplasty-induced restenosis (18, 19) . The NO-cGMP signaling pathway, with sGC as the gate-keeper enzyme, has an important role in inhibiting vascular constriction, platelet adhesion and aggregation, SMC proliferation, and many other physiological processes (8, 20 -22) . Therefore sGC has been regarded as an important target protein to develop therapeutic drugs such as nitrovasodilators or new antithrombotic agents. However, even NO is generally accepted as a potent activator of sGC, the potential to generate peroxynitrite and hydroxyl radicals (23, 24) has significantly limited the clinical applications of nitrovasodilators. YC-1, a NO-independent activator of the sGC, may represent a novel class of drugs sensitizing the enzyme towards its physiological activator without the adverse effects of NO. Previous studies have shown that YC-1 inhibited VSMC proliferation as well as enhancing cGMP production in a dose-dependent fashion (4) . Such inhibition may indicate one of the preventive mechanisms of YC-1 on balloon injury-induced vascular stenosis (11) . In addition, since NO was found to stimulate sGC activity up to 400-fold (25) and YC-1 can potentiate NO-induced sGC activation (26) , co-administration of NO and YC-1 to balloon injured-vessels locally may exert a more significant reduction on neointima formation. However, the regulation of YC-1 on sGC has not been elucidated on the molecular levels. In the present study, our results demonstrated a concentration-dependent activation of YC-1 on both the transcriptional and translational levels of sGC. These results are in agreement with previous reports stating the stimulatory effects of YC-1 on cGMP content and GC activity in VSMC (5, 8) .
TGF-b is another molecule thought to be responsible for cell proliferation. This molecule has been reported to stimulate the cell growth of articular chondrocyte through activation of p44 / 42 MAP kinase (ERK) (27) , as well as the cell proliferation of human coronary SMCs (28) . The significant amount of TGF-b 1 secretion from injured SMCs in rat carotid arteries has also been documented (12) . These observations implicate an important role of TGF-b1 involved in the balloon injuryinduced SMC proliferation. It was therefore rational to determine if TGF-b 1 was involved in the inhibition of YC-1 on cell proliferation. Our results demonstrated the inhibitory effects of YC-1 on cellular content of TGF-b1 providing additional mechanism of YC-1 in preventing balloon injury-induced neointima formation.
FAK is a non-receptor protein tyrosine kinase responsible for cell survival, cell cycle progression, and cell motility (29) . This protein localizes to focal contact sites of cells and recruits Src-family protein tyrosine kinases and adaptor proteins such as p130Cas and Grb 7 upon activation of integrin receptor by extracellular matrix components (e.g., fibronectin, laminin, collagen) (30, 31) . It has been shown that elevated tyrosine phosphatase activity or over-expression of the FAKrelated non-kinase (FRNK), a dominant-negative inhibitor of FAK, reduced the expression of FAK which in turn inhibited FAK-mediated cell motility and proliferation (32 -35) . A recent report demonstrated that transfection of adenovirus-mediated FRNK into balloon injured-rat carotid artery significantly reduced neointima formation, suggesting the involvement of FAK in neointimal formation (36, 37) . These results support our finding that YC-1-mediated inhibition on FAK protein expression level is responsible for in vivo suppression of YC-1 on balloon injury-induced stenosis. Sinnaeve et al. reported that balloon-induced vascular injury was found to decrease sGC subunit expression and enzyme activity in rat carotid arteries (38) . Together with the in vitro and in vivo results, this study demonstrates that YC-1 inhibits VSMC proliferation via the GC / cGMP pathway. This observation is further supported by our findings that YC-1-mediated suppression on neointima formation was prevented by ODQ, a selective inhibitor of GC. In addition, ODQ has been found to reverse the inhibitory effects of YC-1 on SMC proliferation and cyclic GMP-elevating activity of YC-1 (39).
Although our study was designed deliberately to explore the molecular mechanisms of YC-1 in preventing balloon injury-induced stenosis, several questions remain to be answered in the future studies. One thing worth noting is that the serum concentration of YC-1 via the pluronic gel delivery was not determined in the present study. Whether the peak concentration of YC-1 is reached at the initial stage of drug administration or at a later time point needs to be carefully evaluated in subsequent studies. The in vivo toxicology of YC-1 also needs to be further identified. However, the informative results on YC-1 from the current study may shed the light into an effective pharmacological approach alternative to developing gene therapy for preventing PTCAinduced restenosis.
